CN106266239A - Improve compositions of memory and its preparation method and application - Google Patents
Improve compositions of memory and its preparation method and application Download PDFInfo
- Publication number
- CN106266239A CN106266239A CN201610820506.6A CN201610820506A CN106266239A CN 106266239 A CN106266239 A CN 106266239A CN 201610820506 A CN201610820506 A CN 201610820506A CN 106266239 A CN106266239 A CN 106266239A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- ginseng
- extract
- wolfberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 40
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 39
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 39
- 235000008434 ginseng Nutrition 0.000 claims abstract description 39
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 38
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 36
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 36
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 31
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract 13
- 239000000284 extract Substances 0.000 claims description 51
- 244000241838 Lycium barbarum Species 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 239000012141 concentrate Substances 0.000 claims description 19
- 241000736075 Schisandra Species 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 24
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 241000721047 Danaus plexippus Species 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 206010027175 memory impairment Diseases 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 244000241872 Lycium chinense Species 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 208000028698 Cognitive impairment Diseases 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 208000010877 cognitive disease Diseases 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 32
- 240000005373 Panax quinquefolius Species 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000011534 incubation Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008678 sanqi Substances 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- -1 carotenoid esters Chemical class 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种改善记忆的组合物及其制备方法和应用,属于医药技术领域。该组合物的有效成分由以下重量份的药材制备而成:五味子2‑6份,人参3‑9份,三七1‑3份,枸杞6‑12份。方中,针对老年痴呆症这一病因病机,选用滋肾填精、补气散瘀为治法,以五味子益气敛阴、滋补肾精为君药,以人参和三七补气益智、活血散瘀共为臣药,以枸杞子补肾益精、扶养正气为佐药,用以促进老年人记忆和认知障碍的恢复,为开发改善记忆作用的中药及保健食品提供依据。The invention relates to a composition for improving memory, a preparation method and application thereof, and belongs to the technical field of medicine. The active ingredients of the composition are prepared from the following medicinal materials in parts by weight: 2-6 parts of schisandra, 3-9 parts of ginseng, 1-3 parts of panax notoginseng, and 6-12 parts of wolfberry. In the prescription, aiming at the etiology and pathogenesis of senile dementia, nourishing kidney and nourishing essence, invigorating qi and dispelling blood stasis are used as the treatment method, Schisandra chinensis is used as the monarch drug to replenish qi and restrain yin, and nourishing kidney essence, and ginseng and Panax notoginseng are used to nourish qi and improve intelligence. , promoting blood circulation and dissipating blood stasis are used as ministerial medicines, and Chinese wolfberry is used as an adjuvant medicine to nourish kidney and essence, and support righteousness, to promote the recovery of memory and cognitive impairment of the elderly, and to provide a basis for the development of traditional Chinese medicine and health food for improving memory.
Description
技术领域technical field
本发明涉及医药及食品技术领域,特别是涉及一种改善记忆的组合物及其制备方法和应用。The invention relates to the technical fields of medicine and food, in particular to a memory-improving composition and its preparation method and application.
背景技术Background technique
记忆力减退,中医称健忘、善忘、喜忘。本病临床以老年人多见,故常称为老年痴呆。我国传统医学认为,老年痴呆症属于中医“呆病”的范畴,《素问·五藏生成篇》有云:“诸髓者,皆属于脑”,《灵枢·海论》曰:“脑为髓之海,其输上在于其盖,下在风府”,《医学入门》云:“脑者,髓之海,诸髓皆属于脑,故上至脑,下至尾骶,皆精髓升降之道路也”,以上论述均说明脑为髓汇集之处。由此可知,脑髓充旺与否会直接影响脑主神明之用,人脑之主记忆也必然要以脑髓为物质基础和源泉所在,只有髓海充足、脑得滋养,才能发挥正常的学习记忆思维等功能。脑髓的充旺,其与五脏六腑都有关系,但尤以肾为要。肾为先天之本,封藏之本,藏精生髓而上通于脑,正如《灵枢·经脉》云:“人始生,先成精,精成而脑髓生”,清代唐容川在其《医经精义》中也说“事物之所以不忘,赖此记性,记在何处,则在肾精。益肾生精,化为髓,而藏之于脑中”,可见肾精是充养脑髓的主要物质源泉,精充则髓满,精亏则髓空。故临床上应以补肾填精为基本治法,同时老年人由于气虚体质而多有气血瘀阻之症候,阻碍了肾精对髓海的补养。Memory loss, traditional Chinese medicine called forgetfulness, forgetfulness, happy forgetfulness. The disease is more common in the elderly clinically, so it is often called senile dementia. Traditional Chinese medicine believes that Alzheimer's disease belongs to the category of "dementia" in traditional Chinese medicine. It is said in "Su Wen Wu Zang Cheng Sheng Pian": "All the marrow belongs to the brain", "Lingshu Hai Lun" says: "The brain It is the sea of marrow, its infusion lies in its lid, and its infusion lies in Fengfu." "Introduction to Medicine" says: "The brain is the sea of marrow. All the marrow belongs to the brain, so it goes up to the brain and down to the tail sacrum. The way of ascending and descending", the above discussion all show that the brain is the place where the marrow gathers. It can be seen from this that whether the brain is full or not will directly affect the use of the brain to govern the gods. The memory of the human brain must also be based on the brain as the material basis and source. Only when the marrow is sufficient and the brain is nourished can normal learning and memory be developed. thinking functions. The fullness of the brain is related to the internal organs, but especially the kidneys. The kidney is the foundation of congenital nature, the foundation of sealing and storing, storing the essence to produce marrow and then leading to the brain, just as the "Lingshu Meridians" says: "People are born, first become essence, and after essence is formed, the brain marrow grows." In the Qing Dynasty, Tang Rongchuan Its "Medical Classics Essence" also said that "the reason why things are not forgotten depends on this memory. Where they are remembered, it is in the kidney essence. The kidney produces essence, which turns into marrow and stores it in the brain." It can be seen that the kidney Essence is the main source of material to nourish the brain, when the essence is full, the marrow will be full, and if the essence is deficient, the marrow will be empty. Therefore, in clinical practice, tonifying the kidney and replenishing the essence should be the basic treatment method. At the same time, the elderly often have symptoms of qi and blood stasis due to qi deficiency, which hinders the nourishment of the kidney essence to the marrow sea.
发明内容Contents of the invention
基于此,本发明的目的在于提供一种改善记忆的组合物,该组合物针对老年人的特点,具有较好的改善记忆力的作用。Based on this, the object of the present invention is to provide a memory-improving composition, which is aimed at the characteristics of the elderly and has a better memory-improving effect.
一种改善记忆的组合物,所述组合物的有效成分由以下重量份的药材制备而成:A composition for improving memory, the active ingredient of which is prepared from the following medicinal materials in parts by weight:
五味子2-6份,人参3-9份,三七1-3份,枸杞6-12份。2-6 parts of schisandra, 3-9 parts of ginseng, 1-3 parts of Panax notoginseng, 6-12 parts of wolfberry.
本发明依据传统中医药理论,并结合现代医学,选用了五味子,人参,三七和枸杞进行配伍,方中:According to the theory of traditional Chinese medicine and combined with modern medicine, the present invention selects schisandra chinensis, ginseng, notoginseng and medlar for compatibility. In the formula:
五味子,味酸、甘,性温,归肺、心、肾经。具有收敛固涩,益气生津,补肾宁心的功效。用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠等。五味子主要成分是木脂素和多糖,现代药理学研究表明,五味子具有明显的降脂保肝、镇静安神和抗氧化的作用。本方中重用五味子为君药,旨在发挥其益气敛阴、滋补肾精的功效。Schisandra chinensis, sour in taste, sweet in taste, warm in nature, returns to lung, heart and kidney channels. It has the effects of astringent and astringent, nourishing qi and promoting body fluid, invigorating the kidney and calming the heart. For chronic cough and shortness of breath, nocturnal spermatorrhea, enuresis, frequent urination, chronic diarrhea, spontaneous sweating, night sweats, thirsty wounds, shortness of breath, internal heat and thirst, palpitations, insomnia, etc. The main components of Schisandra are lignans and polysaccharides. Modern pharmacological studies have shown that Schisandra has obvious effects of lowering fat, protecting liver, calming nerves and anti-oxidation. Schisandra chinensis is reused as the monarch drug in this prescription, aiming to exert its effects of nourishing qi, restraining yin and nourishing kidney essence.
人参,味甘、微苦,性平、微温,归脾、肺、心经。功效为大补元气,补脾益肺,生津止渴,安神益智,补一切虚。人参的主要成分是人参皂苷、多糖和挥发油。三七,味甘、微苦,性温,归肝、胃经。具有散瘀止血、消肿定痛的功效,主要用于治疗衄血、便血、崩漏、咯血、吐血、外伤出血、胸腹刺痛等症。现代药学研究证实,三七主要包括皂苷、黄酮类化合物,能够改善心肌供血和扩张冠脉,此外三七中谷甾醇和胡萝卜苷还具有降血脂的作用。方中以人参和三七共为臣药,在辅助君药五味子发挥益气固本作用的同时,起到安神益智、填补髓海空虚的作用。Ginseng, sweet in taste, slightly bitter, neutral in nature, slightly warm, returns to the spleen, lung, and heart channels. The effect is to invigorate vital energy, invigorate the spleen and lungs, promote body fluid and quench thirst, soothe the nerves and improve the mind, and tonify all deficiencies. The main components of ginseng are ginsenosides, polysaccharides and volatile oils. Notoginseng, sweet in taste, slightly bitter, warm in nature, returns to liver and stomach meridian. It has the effects of dispelling blood stasis and stopping bleeding, reducing swelling and relieving pain, and is mainly used to treat epistaxis, blood in the stool, metrorrhagia, hemoptysis, hematemesis, traumatic bleeding, chest and abdomen tingling and other diseases. Modern pharmaceutical research has confirmed that notoginseng mainly includes saponins and flavonoids, which can improve myocardial blood supply and dilate coronary arteries. In addition, sitosterol and carotin in notoginseng also have the effect of lowering blood lipids. In the prescription, ginseng and Panax notoginseng are used as ministerial drugs. While assisting the monarch drug Schisandra to exert the effect of nourishing qi and strengthening the root, it also plays the role of calming the nerves, improving intelligence and filling the emptiness of the sea of marrow.
枸杞子,味甘、性平;归肝、肾、肺经。具有补肾益精,养肝明目,润肺生津等功效。用于虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明。枸杞子的主要成分是枸杞多糖、甜菜碱、类胡萝卜素和类胡萝卜酯以及多种维生素和氨基酸,大量文献报道,枸杞具有提高免疫力,调节神经系统功能,保肝、降血压、降血脂、降血糖和延缓衰老的作用。本方以枸杞子为佐药,用以补肾益精、扶养正气,通过提高机体免疫能力而发挥延缓衰老、增强记忆能力的作用。Fructus Lycium barbarum, sweet in taste, flat in nature; returns liver, kidney, lung meridian. It has the effects of invigorating the kidney and essence, nourishing the liver and improving eyesight, moistening the lungs and promoting body fluid. It is used for consumptive essence deficiency, soreness of waist and knees, dizziness and tinnitus, internal heat and thirst, blood deficiency and chlorosis, and blurred vision. The main components of Lycium barbarum are Lycium barbarum polysaccharides, betaine, carotenoids and carotenoid esters, and various vitamins and amino acids. According to a large number of literature reports, Lycium barbarum can improve immunity, regulate nervous system function, protect liver, lower blood pressure, lower blood fat, Hypoglycemic and anti-aging effects. This prescription uses Lycium barbarum as an adjuvant drug to invigorate the kidneys and essence, support righteousness, and play the role of delaying aging and enhancing memory ability by improving the body's immune ability.
据此,本发明重用五味子为君药,旨在发挥其益气敛阴、滋补肾精的功效;以人参和三七共为臣药,在辅助君药五味子发挥益气固本作用的同时,起到安神益智、填补髓海空虚的作用;并以枸杞子为佐药,用以补肾益精、扶养正气,通过提高机体免疫能力而发挥延缓衰老、增强记忆能力的作用。Accordingly, the present invention reuses Schisandra chinensis as the monarch drug, aiming to bring into play its effect of replenishing qi and restraining yin and nourishing kidney essence; taking ginseng and Radix Notoginseng as ministerial drugs, while assisting the monarch drug Schisandra chinensis to exert the effect of nourishing qi and consolidating the root, It plays the role of calming the nerves and improving the mind and filling the emptiness of the sea of marrow; and the fruit of wolfberry is used as an adjuvant to nourish the kidney and essence, nourish the righteousness, and play the role of delaying aging and enhancing memory by improving the body's immunity.
在其中一个实施例中所述组合物的有效成分由以下重量份的药材制备而成:In one of the embodiments, the active ingredients of the composition are prepared from the following medicinal materials in parts by weight:
五味子6份,人参9份,三七1份,枸杞6份。6 parts of schisandra, 9 parts of ginseng, 1 part of Panax notoginseng, 6 parts of wolfberry.
本法明还公开了上述的改善记忆的组合物的制备方法,包括以下步骤:This Faming also discloses the preparation method of the above memory-improving composition, comprising the following steps:
五味子提取:按重量份称取五味子,加入体积百分含量为60%-90%的乙醇水溶液,50-80℃提取,过滤,滤液浓缩,得五味子流浸膏;Extraction of Schisandra chinensis: Weigh Schisandra chinensis in parts by weight, add ethanol aqueous solution with a volume percentage of 60%-90%, extract at 50-80°C, filter, and concentrate the filtrate to obtain Schisandra chinensis liquid extract;
人参提取:按重量份称取人参,加入体积百分含量为60%-100%的乙醇水溶液,70-100℃提取,过滤,滤液浓缩,得人参流浸膏;Ginseng extraction: Weigh ginseng by weight, add ethanol aqueous solution with a volume percentage of 60%-100%, extract at 70-100°C, filter, and concentrate the filtrate to obtain ginseng liquid extract;
三七提取:按重量份称取三七,加入体积百分含量为30%-70%的乙醇水溶液,50-90℃提取,过滤,滤液浓缩,得三七流浸膏;Radix Notoginseng Extraction: Weigh Radix Notoginseng by weight, add an aqueous ethanol solution with a volume percentage of 30%-70%, extract at 50-90°C, filter, and concentrate the filtrate to obtain a liquid extract of Notoginseng;
枸杞提取:按重量份称取枸杞,加入体积百分含量为0%-30%的乙醇水溶液,80-100℃提取,过滤,滤液浓缩,得枸杞流浸膏;Lycium barbarum extraction: Weigh wolfberry by weight, add ethanol aqueous solution with a volume percentage of 0%-30%, extract at 80-100°C, filter, and concentrate the filtrate to obtain wolfberry liquid extract;
混合:取上述五味子流浸膏、人参流浸膏、三七流浸膏和枸杞流浸膏,混合均匀,即得。Mixing: Take the above-mentioned schisandra liquid extract, ginseng liquid extract, notoginseng liquid extract and wolfberry liquid extract, mix evenly, and obtain.
上述制备方法,将药材中的有效成分进行提取,提高了患者服用的便利性,并且该制备方法工艺简单易行,易于进行工业生产。The above preparation method extracts the active ingredients in the medicinal materials, which improves the convenience for patients to take, and the preparation method has a simple process and is easy to carry out industrial production.
在其中一个实施例中,所述五味子提取中,按重量份称取五味子,按每克五味子加入10-18ml体积百分含量为70%-80%的乙醇水溶液,60-70℃提取1-3hr,过滤,滤液浓缩,得五味子流浸膏。In one of the embodiments, in the extraction of Schisandra chinensis, take Schisandra chinensis by weight, add 10-18ml of ethanol aqueous solution with a volume percentage of 70%-80% per gram of Schisandra chinensis, and extract at 60-70°C for 1-3hr , filtered, and the filtrate was concentrated to obtain Schisandra extract.
在其中一个实施例中,所述人参提取中,按重量份称取人参,按每克人参加入7-13ml体积百分含量为75%-85%的乙醇水溶液,80-90℃提取1-3次,每次1-3hr,过滤,合并滤液后浓缩,得人参流浸膏。In one of the embodiments, in the extraction of ginseng, ginseng is weighed in parts by weight, 7-13ml of ethanol aqueous solution with a volume percentage of 75%-85% is added per gram of ginseng, and 1-3 times, 1-3hr each time, filter, combine and concentrate the filtrates to obtain ginseng fluid extract.
在其中一个实施例中所述三七提取中,按重量份称取三七,按每克三七加入6-10ml体积百分含量为45%-55%的乙醇水溶液,65-75℃提取1-3次,每次1-3hr,过滤,合并滤液后浓缩,得三七流浸膏。In the extraction of Panax notoginseng in one of the examples, weigh Panax notoginseng by weight, add 6-10ml of ethanol aqueous solution with a volume percentage of 45%-55% per gram of Panax notoginseng, and extract at 65-75°C for 1 -3 times, 1-3hr each time, filter, combine and concentrate the filtrates to obtain a notoginseng liquid extract.
在其中一个实施例中所述枸杞提取中,按重量份称取枸杞,按每克枸杞加入7-13ml水,90-100℃提取1-3次,每次1-3hr,过滤,合并滤液后浓缩,得枸杞流浸膏。In the wolfberry extraction described in one of the examples, take wolfberry by weight, add 7-13ml of water per gram of wolfberry, extract 1-3 times at 90-100°C, 1-3hr each time, filter, and combine the filtrates Concentrate to get wolfberry liquid extract.
本发明还公开了上述的组合物在制备具有改善记忆作用的药物制剂或保健品制剂中的应用。The invention also discloses the application of the above-mentioned composition in the preparation of pharmaceutical preparations or health care preparations with memory-improving effects.
在其中一个实施例中,所述药物制剂为口服液、硬胶囊、软胶囊、片剂、丸剂、滴丸剂、颗粒剂、散剂、蜜膏剂或露剂。In one of the embodiments, the pharmaceutical preparation is oral liquid, hard capsule, soft capsule, tablet, pill, dropping pill, granule, powder, honey paste or dew.
在其中一个实施例中,所述保健品制剂为袋泡茶或酒剂。In one of the embodiments, the health product preparation is tea in bag or liquor.
与现有技术相比,本发明具有以下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
本发明的改善记忆的组合物,针对老年痴呆症这一病因病机,选用滋肾填精、补气散瘀为治法,以五味子益气敛阴、滋补肾精为君药,以人参和三七补气益智、活血散瘀共为臣药,以枸杞子补肾益精、扶养正气为佐药,用以促进老年人记忆和认知障碍的恢复。The memory-improving composition of the present invention is aimed at the etiology and pathogenesis of senile dementia. Radix Notoginseng nourishes qi and improves intelligence, promotes blood circulation and dissipates blood stasis, and Chinese wolfberry fruit nourishes kidney and essence, and nourishes righteousness as an adjuvant drug to promote the recovery of memory and cognitive impairment in the elderly.
该抗疲劳组合物在中医中药理论基础上,再通过小鼠避暗实验和水迷宫实验进行了功效成分筛选及配方设计,最终才获得的具有明确改善记忆力的中药配方,为开发改善记忆力的中药及保健食品提供依据。Based on the theory of traditional Chinese medicine, the anti-fatigue composition screened the functional components and designed the formula through the mouse dark avoidance experiment and the water maze experiment, and finally obtained the traditional Chinese medicine formula that can clearly improve memory. and health food.
并且,将各原料以特定的比例配合后,具有非常好的效果,口服给予该组合物30天后,进行水迷宫实验,小鼠找到平台的时间与模型组相比,具有显著性差异。Moreover, after mixing each raw material in a specific ratio, it has a very good effect. After 30 days of oral administration of the composition, the water maze test is carried out, and the time for the mice to find the platform is significantly different from that of the model group.
具体实施方式detailed description
以下结合具体实施例来详细解释说明本发明,但并不对本发明造成任何限制。The present invention is explained in detail below in conjunction with specific examples, but does not impose any limitation on the present invention.
以下实施例中所采用的原料药及辅料均为普通市售。The bulk drugs and adjuvants used in the following examples are all commercially available.
实施例1Example 1
一种改善记忆的组合物,由以下药材制备而成:A composition for improving memory, prepared from the following medicinal materials:
五味子6g,人参9 g,三七1 g,枸杞6 g。Schisandra 6g, ginseng 9g, Sanqi 1g, wolfberry 6g.
将上述原料按下列步骤制备:The above raw materials are prepared according to the following steps:
五味子提取:按重量份称取五味子,按每克五味子加入14ml体积百分含量为75%的乙醇水溶液,65℃水浴提取2hr,过滤,滤液浓缩,得五味子流浸膏。Extraction of Schisandra: Weigh Schisandra by weight, add 14 ml of 75% ethanol aqueous solution per gram of Schisandra, extract in a water bath at 65°C for 2 hours, filter, and concentrate the filtrate to obtain Schisandra liquid extract.
人参提取:按重量份称取人参,按每克人参加入10ml体积百分含量为80%的乙醇水溶液,85℃水浴提取2次,每次1hr,过滤,合并滤液后浓缩,得人参流浸膏。Ginseng extraction: Weigh ginseng by weight, add 10ml of 80% ethanol aqueous solution per gram of ginseng, extract in 85°C water bath twice, 1hr each time, filter, combine the filtrates and concentrate to obtain ginseng liquid extract .
三七提取:按重量份称取三七,按每克三七加入8ml体积百分含量为50%的乙醇水溶液,70℃水浴提取2次,每次2hr,过滤,合并滤液后浓缩,得三七流浸膏。Panax notoginseng extraction: take panax notoginseng by weight, add 8ml of ethanol aqueous solution with a volume percentage of 50% per gram of panax notoginseng, extract 2 times in a water bath at 70°C, each time for 2hr, filter, and concentrate after combining the filtrates to obtain Sanqi Qiliu extract.
枸杞提取:按重量份称取枸杞,按每克枸杞加入10ml水,100℃提取3次,每次3hr,过滤,合并滤液后浓缩,得枸杞流浸膏。Lycium barbarum extraction: Weigh wolfberry by weight, add 10ml of water per gram of wolfberry, extract 3 times at 100°C, 3 hours each time, filter, combine filtrates and concentrate to obtain wolfberry liquid extract.
混合:取上述五味子流浸膏、人参流浸膏、三七流浸膏和枸杞流浸膏,混合均匀,干燥,即得改善记忆的组合物A。Mixing: take the above-mentioned schisandra liquid extract, ginseng liquid extract, notoginseng liquid extract and wolfberry liquid extract, mix evenly, and dry to obtain composition A for improving memory.
实施例2Example 2
一种改善记忆的组合物,由以下药材制备而成:A composition for improving memory, prepared from the following medicinal materials:
五味子2g,人参9 g,三七3g,枸杞12 g。Schisandra 2g, ginseng 9g, Sanqi 3g, wolfberry 12g.
按照实施例1的方法制备,得到改善记忆的组合物B。Prepared according to the method of Example 1, the composition B for improving memory was obtained.
对比例1Comparative example 1
本对比例制备一种组合物,与实施例1的改善记忆的组合物基本相同,不同之处在于,本对比例的组合物由以下药材制备而成:This comparative example prepares a composition, which is basically the same as the memory-improving composition of Example 1, except that the composition of this comparative example is prepared from the following medicinal materials:
五味子6g,人参9 g,三七1 g。Schisandra 6g, ginseng 9g, Sanqi 1g.
参照实施例1的方法制备得到组合物C。Composition C was prepared with reference to the method of Example 1.
对比例2Comparative example 2
本对比例制备一种组合物,与实施例1的改善记忆的组合物基本相同,不同之处在于,本对比例的组合物由以下药材制备而成:This comparative example prepares a composition, which is basically the same as the memory-improving composition of Example 1, except that the composition of this comparative example is prepared from the following medicinal materials:
五味子6g,三七1 g,枸杞6 g。Schisandra 6g, Panax notoginseng 1g, wolfberry 6g.
参照实施例1的方法制备得到组合物D。Composition D was prepared according to the method of Example 1.
对比例3Comparative example 3
本对比例制备一种组合物,与实施例1的改善记忆的组合物基本相同,不同之处在于,本对比例的组合物由以下药材制备而成:This comparative example prepares a composition, which is basically the same as the memory-improving composition of Example 1, except that the composition of this comparative example is prepared from the following medicinal materials:
人参9 g,三七1 g,枸杞6 g。9 g ginseng, 1 g Panax notoginseng, 6 g wolfberry.
参照实施例1的方法制备得到组合物E。Composition E was prepared with reference to the method of Example 1.
对比例4Comparative example 4
本对比例制备一种组合物,与实施例1的改善记忆的组合物基本相同,不同之处在于,本对比例的组合物由以下药材制备而成:This comparative example prepares a composition, which is basically the same as the memory-improving composition of Example 1, except that the composition of this comparative example is prepared from the following medicinal materials:
五味子6g,人参9 g,枸杞6 g。Schisandra 6g, ginseng 9g, wolfberry 6g.
参照实施例1的方法制备得到组合物F。Composition F was prepared according to the method of Example 1.
对比例5Comparative example 5
本对比例制备一种组合物,与实施例1的改善记忆的组合物基本相同,不同之处在于,本对比例的组合物由以下药材制备而成:This comparative example prepares a composition, which is basically the same as the memory-improving composition of Example 1, except that the composition of this comparative example is prepared from the following medicinal materials:
五味子6g,人参9 g,三七1 g,枸杞6 g、益智仁6g。Schisandra 6g, ginseng 9g, Sanqi 1g, wolfberry 6g, Yizhiren 6g.
参照实施例1的方法制备得到组合物G。Composition G was prepared according to the method of Example 1.
实验例1Experimental example 1
取上述实施例和对比例制备得到的组合物,进行小鼠避暗实验,方法如下:Get the composition that above-mentioned embodiment and comparative example prepare, carry out mouse dark avoidance test, method is as follows:
1、实验动物。1. Experimental animals.
健康ICR雄性小鼠,体重20±2g,由吉林大学实验动物研究中心提供,许可证号为SCXK-(吉)2015-0005,分笼后放于安静、温湿度适宜、通风良好的环境中,自由饮水,合理摄食,适应所处环境7天后开始实验。Healthy ICR male mice, weighing 20±2g, were provided by the Experimental Animal Research Center of Jilin University with the license number SCXK-(Ji)2015-0005. Drinking water freely, ingesting food reasonably, and starting the experiment after 7 days of adaptation to the environment.
2、实验方法。2. Experimental method.
将ICR小鼠随机分为空白对照组(灌胃给予蒸馏水)、组合物A组、组合物B组、组合物C组、组合物D组、组合物E组、组合物F组、组合物G组,对小鼠进行为期30天的连续灌胃给药,给药剂量为0.1ml/10g(组合物配制浓度为0.366g/ml)。The ICR mice were randomly divided into blank control group (distilled water administered by intragastric administration), composition A group, composition B group, composition C group, composition D group, composition E group, composition F group, composition G group, the mice were continuously orally administered for 30 days, and the dosage was 0.1ml/10g (the concentration of the composition was 0.366g/ml).
第29天灌胃30 min后,进行避暗实验。即将小鼠放入避暗仪中面部背向洞口放入明室,同时启动计时器。以小鼠进入洞口到达暗室受到错误时计时器记录的时间即为潜伏期。本实验对小鼠训练5 min,并记录在5 min内小鼠的错误次数。于次日给药30分钟后进行第二次试验。记录每只鼠的潜伏期以及在5min内出现的错误次数。On the 29th day, after gavage for 30 minutes, the dark avoidance experiment was carried out. That is to say, put the mouse into the dark room with its face facing away from the hole in the dark avoidance instrument, and start the timer at the same time. The time recorded by the timer when the mouse entered the hole and arrived at the dark room was the incubation period. In this experiment, the mice were trained for 5 minutes, and the number of mistakes made by the mice within 5 minutes was recorded. The second test was carried out 30 minutes after administration on the next day. The incubation period of each mouse and the number of errors that occurred within 5 min were recorded.
3、实验结果。3. Experimental results.
实验结果如下表所示。The experimental results are shown in the table below.
表1.各组小鼠避暗试验结果(, n=15)Table 1. The results of the dark avoidance test for mice in each group ( , n=15)
注:与正常组比较,*P<0.05。Note: Compared with normal group, *P<0.05.
上述结果表明,经连续灌胃给药30天的小鼠,与空白对照的小鼠比较,小鼠避暗试验中错误次数明显减少。The above results show that the number of errors in the dark avoidance test of the mice after continuous intragastric administration for 30 days was significantly reduced compared with the blank control mice.
并且,本发明的组合物中,每一味药材的缺失,都对本品的改善记忆效果产生一定的影响,故四味中药材缺一不可,并且增加一味药材,其效果也不如这四味中药材的配伍。与实施例2相比,采用实施例1的最佳配比,具有最优的改善记忆效果。Moreover, in the composition of the present invention, the lack of each medicinal material will have a certain impact on the memory-improving effect of this product, so the four traditional Chinese medicinal materials are indispensable, and the effect of adding one medicinal material is not as good as these four traditional Chinese medicines. Material compatibility. Compared with Example 2, adopting the optimal proportion of Example 1 has the best effect of improving memory.
实验例2Experimental example 2
取上述实施例1制备得到的组合物A,进行小鼠避暗试验,方法如下:Get the composition A prepared in the above-mentioned Example 1, and carry out the mouse dark avoidance test, the method is as follows:
1、实验动物。1. Experimental animals.
健康ICR雄性小鼠,体重20±2g,由吉林大学实验动物研究中心提供,许可证号为SCXK-(吉)2015-0005,分笼后放于安静、温湿度适宜、通风良好的环境中,自由饮水,合理摄食,适应所处环境7天后开始实验。Healthy ICR male mice, weighing 20±2g, were provided by the Experimental Animal Research Center of Jilin University with the license number SCXK-(Ji)2015-0005. Drinking water freely, ingesting food reasonably, and starting the experiment after 7 days of adaptation to the environment.
2、实验方法。2. Experimental method.
将ICR小鼠随机分为空白对照组(灌胃给予蒸馏水)、模型组(灌胃给予蒸馏水,腹腔注射东莨菪碱5mg/kg)、组合物A低剂量组、组合物A中剂量组,组合物A高剂量组,将各组小鼠按0.1ml/10g容量连续灌胃给药30天,每天一次。(组合物A低、中、高剂量配制浓度分别为0.183g/ml、0.366 g/ml、0.732g/ml)。The ICR mice were randomly divided into blank control group (distilled water by intragastric administration), model group (distilled water administered by intragastric administration, scopolamine 5 mg/kg intraperitoneal injection), low-dose composition A group, medium-dose composition A group, composition A In the high-dose group, the mice in each group were administered by intragastric administration at a volume of 0.1ml/10g for 30 days, once a day. (The low, medium and high doses of composition A are formulated at concentrations of 0.183 g/ml, 0.366 g/ml and 0.732 g/ml, respectively).
于灌胃第29天及第30天开始进行避暗试验。第29天开始训练,在训练前30 min进行灌胃给药,灌胃给药20min后,空白对照组小鼠腹腔注射生理盐水,模型组和其它各组小鼠腹腔注射5mg/kg氢溴酸东莨菪碱。腹腔注射10min后,将小鼠放入避暗仪中面部背向洞口放入明室,同时启动计时器。以小鼠进入洞口到达暗室受到错误时计时器记录的时间即为潜伏期。本实验对小鼠训练5 min,并记录在5 min内小鼠的错误次数。于灌胃给药第30天进行第二次试验,给药方法同第29天。记录每只鼠的潜伏期以及在5min内出现的错误次数。On the 29th day and the 30th day of gavage, the dark avoidance test was carried out. On the 29th day, the training was started, and 30 minutes before the training, intragastric administration was carried out. After 20 minutes of intragastric administration, the mice in the blank control group were injected with normal saline intraperitoneally, and the mice in the model group and other groups were injected with 5 mg/kg hydrobromic acid intraperitoneally. Scopolamine. After 10 minutes of intraperitoneal injection, put the mouse into the dark room with the face back to the hole in the dark avoidance instrument, and start the timer at the same time. The time recorded by the timer when the mouse entered the hole and arrived at the dark room was the incubation period. In this experiment, the mice were trained for 5 minutes, and the number of mistakes made by the mice within 5 minutes was recorded. The second test was carried out on the 30th day of intragastric administration, and the administration method was the same as that on the 29th day. Record the incubation period of each mouse and the number of errors that occurred within 5 minutes.
3、实验结果。3. Experimental results.
实验结果如下表所示。The experimental results are shown in the table below.
表2.各组小鼠避暗试验结果(, n=15)Table 2. The results of the dark avoidance test for mice in each group ( , n=15)
注:与空白组比较,**P<0.01;与模型组比较,#P<0.05,##P<0.01;与中剂量组比较,▲P<0.05,▲▲P<0.01。Note: Compared with the blank group, **P<0.01; compared with the model group, #P<0.05, ##P<0.01; compared with the middle dose group, ▲P<0.05, ▲▲P<0.01.
上述结果表明,与空白组比较,模型组小鼠潜伏期明显缩短(P<0.01),错误次数明显增加(P<0.01),表明造模成功;与模型组比较,中、高剂量组小鼠潜伏期明显延长(P<0.05,P<0.01),错误次数明显减少(P<0.05,P<0.01);且随着给药剂量的增加,潜伏期逐渐延长(低剂量组和高剂量组分别与中剂量组比较,P<0.05,P<0.01),错误次数逐渐减少(低剂量组和高剂量组分别与中剂量组比较,P<0.05)。实验结果表明,上述组合物具有改善记忆作用,且该作用存在剂量依赖性。The above results showed that compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.01), and the number of mistakes was significantly increased (P<0.01), indicating that the modeling was successful; compared with the model group, the incubation period of the mice in the middle and high dose groups Significantly prolonged (P<0.05, P<0.01), the number of errors was significantly reduced (P<0.05, P<0.01); and with the increase of the dosage, the latency period was gradually extended (low-dose group and high-dose group were respectively compared with middle-dose group comparison, P<0.05, P<0.01), and the number of errors gradually decreased (low-dose group and high-dose group were compared with middle-dose group, P<0.05). Experimental results show that the composition has the effect of improving memory, and the effect is dose-dependent.
实验例3Experimental example 3
取上述实施例和对比例制备得到的组合物,进行小鼠Morris水迷宫实验,方法如下:Get the composition that above-mentioned embodiment and comparative example prepare, carry out mouse Morris water maze experiment, method is as follows:
1、实验动物。1. Experimental animals.
健康ICR雄性小鼠,体重20±2g,由吉林大学实验动物研究中心提供,许可证号为SCXK-(吉)2015-0005,分笼后放于安静、温湿度适宜、通风良好的环境中,自由饮水,合理摄食,适应所处环境7天后开始实验。Healthy ICR male mice, weighing 20±2g, were provided by the Experimental Animal Research Center of Jilin University with the license number SCXK-(Ji)2015-0005. Drinking water freely, ingesting food reasonably, and starting the experiment after 7 days of adaptation to the environment.
2、实验方法。2. Experimental method.
将ICR小鼠随机分为空白对照组(灌胃给予蒸馏水)、模型组(灌胃给予蒸馏水,腹腔注射东莨菪碱5mg/kg)、组合物A组、组合物B组、组合物C组、组合物D组、组合物E组、组合物F组、组合物G组,将各组小鼠按0.1ml/10g容量连续灌胃给药30天,每天一次。给药剂量为0.1ml/10g(组合物配制浓度为0.366g/ml)。The ICR mice were randomly divided into blank control group (distilled water was given by intragastric administration), model group (distilled water was given by intragastric administration, and 5 mg/kg scopolamine was injected intraperitoneally), composition A group, composition B group, composition C group, and composition D group, composition E group, composition F group, and composition G group, the mice in each group were administered intragastrically at a volume of 0.1 ml/10 g for 30 days, once a day. The dosage is 0.1ml/10g (the concentration of the composition is 0.366g/ml).
于灌胃给药第25天进行水迷宫试验,在训练前30 min进行灌胃给药, 灌胃给药20min后,空白对照组小鼠腹腔注射生理盐水,对模型组、组合物A组、组合物B组、组合物C组、组合物D组、组合物E组、组合物F组、组合物G组进行腹腔注射东莨菪碱5mg/kg。腹腔注射10min后,将小鼠放在Morris水迷宫视频跟踪测试系统WMT-100中,设置小鼠的训练时间设定为120s,在120s内未达到终点的小鼠按120s记录。第一次实验之前将小鼠放在平台附近,使其自动爬上3次。以后每次训练前将小鼠放在平台附近,使其自主爬上到平台一次。每隔24 h训练1次,训练期间继续给药,给药方法同第25天。采集给药第29天的实验数据。给药第30天把平台去掉统计小鼠空间搜索能力,给药方法同第25天。并记录小鼠穿越平台次的数实验结果。On the 25th day of intragastric administration, the water maze test was carried out, and the intragastric administration was carried out 30 minutes before the training. After 20 minutes of intragastric administration, the mice in the blank control group were intraperitoneally injected with normal saline, and the mice in the model group, composition A group, Composition B group, composition C group, composition D group, composition E group, composition F group, composition G group received intraperitoneal injection of scopolamine 5 mg/kg. After 10 minutes of intraperitoneal injection, the mice were placed in the Morris water maze video tracking test system WMT-100, and the training time of the mice was set to 120s, and the mice that did not reach the end point within 120s were recorded as 120s. Before the first experiment, mice were placed near the platform and allowed to climb up 3 times automatically. Before each training, the mice were placed near the platform and allowed to climb up to the platform once. Train every 24 hours, continue to administer medicine during training, and the administration method is the same as that on the 25th day. Collect the experimental data on the 29th day of administration. On the 30th day of administration, the platform was removed to count the spatial search ability of the mice, and the administration method was the same as that on the 25th day. And record the experimental results of the number of times the mice crossed the platform.
2、实验结果。2. Experimental results.
实验结果如下表所示。The experimental results are shown in the table below.
表3各组小鼠水迷宫定位航行和探索结果(, n=15)Table 3 Water maze positioning navigation and exploration results of mice in each group ( , n=15)
注:与空白组比较,**P<0.01;与模型组比较,#P<0.05,##P<0.01。Note: Compared with blank group, **P<0.01; compared with model group, #P<0.05, ##P<0.01.
上述结果表明,与模型组相比,实施例1和2制备的组合物A和B组找到平台时间明显缩短;并且,经过平台次数明显增多。The above results show that, compared with the model group, the time to find the platform of the compositions A and B prepared in Examples 1 and 2 is significantly shortened; and the times of passing the platform are significantly increased.
并且,本发明的组合物中,每一味药材的缺失,都对本品的改善记忆效果产生一定的影响,故四味中药材缺一不可,并且增加一味药材,其效果也不如这四味中药材的配伍。与实施例2相比,采用实施例1的最佳配比,具有最优的改善记忆效果。Moreover, in the composition of the present invention, the lack of each medicinal material will have a certain impact on the memory-improving effect of this product, so the four traditional Chinese medicinal materials are indispensable, and the effect of adding one medicinal material is not as good as these four traditional Chinese medicines. Material compatibility. Compared with Example 2, adopting the optimal proportion of Example 1 has the best effect of improving memory.
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。The technical features of the above-mentioned embodiments can be combined arbitrarily. To make the description concise, all possible combinations of the technical features in the above-mentioned embodiments are not described. However, as long as there is no contradiction in the combination of these technical features, should be considered as within the scope of this specification.
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。The above-mentioned embodiments only express several implementation modes of the present invention, and the descriptions thereof are relatively specific and detailed, but should not be construed as limiting the patent scope of the invention. It should be pointed out that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent for the present invention should be based on the appended claims.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610820506.6A CN106266239B (en) | 2016-09-13 | 2016-09-13 | Memory-improving composition, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610820506.6A CN106266239B (en) | 2016-09-13 | 2016-09-13 | Memory-improving composition, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106266239A true CN106266239A (en) | 2017-01-04 |
CN106266239B CN106266239B (en) | 2019-05-07 |
Family
ID=57711209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610820506.6A Active CN106266239B (en) | 2016-09-13 | 2016-09-13 | Memory-improving composition, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106266239B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107997170A (en) * | 2017-11-30 | 2018-05-08 | 江苏康缘药业股份有限公司 | A kind of composition with hypolipemic function and preparation method thereof |
CN109793834A (en) * | 2019-03-30 | 2019-05-24 | 漯河医学高等专科学校 | A traditional Chinese medicine formula for improving immunity |
CN110522820A (en) * | 2018-05-23 | 2019-12-03 | 山东省农业可持续发展研究所 | A kind of slow health care product and preparation method thereof invigorated that declines of the strong kidney of person in middle and old age |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679849A (en) * | 2005-01-12 | 2005-10-12 | 杜洪录 | Nutritive instant pwoder of ginseng |
-
2016
- 2016-09-13 CN CN201610820506.6A patent/CN106266239B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679849A (en) * | 2005-01-12 | 2005-10-12 | 杜洪录 | Nutritive instant pwoder of ginseng |
Non-Patent Citations (4)
Title |
---|
孙靖辉等: "人参与北五味子配伍前后的抗氧化及促智作用", 《中国老年学杂志》 * |
宋媛等: "参益安神片改善小鼠学习记忆的作用及其机制", 《中国老年学杂志》 * |
江震等: "中药促智作用的内分泌免疫研究进展", 《现代中药研究与实践》 * |
王赟等: "补益类中药及其有效成分对阿尔茨海默病相关学习记忆能力影响的实验研究进展", 《上海中医药杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107997170A (en) * | 2017-11-30 | 2018-05-08 | 江苏康缘药业股份有限公司 | A kind of composition with hypolipemic function and preparation method thereof |
CN107997170B (en) * | 2017-11-30 | 2021-04-20 | 江苏康缘药业股份有限公司 | Composition with blood fat reducing function and preparation method thereof |
CN110522820A (en) * | 2018-05-23 | 2019-12-03 | 山东省农业可持续发展研究所 | A kind of slow health care product and preparation method thereof invigorated that declines of the strong kidney of person in middle and old age |
CN109793834A (en) * | 2019-03-30 | 2019-05-24 | 漯河医学高等专科学校 | A traditional Chinese medicine formula for improving immunity |
Also Published As
Publication number | Publication date |
---|---|
CN106266239B (en) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104666768B (en) | A kind of traditional Chinese medicine health care preparation for being used to nourish qi and blood | |
CN103005445A (en) | Compound healthcare product capable of improving immunity | |
CN103566045B (en) | The preparation method of the pharmaceutical composition of improving water flood | |
CN102228595A (en) | Chinese prescription energy pure Chinese medicine extract with anti-aging function | |
CN106266239A (en) | Improve compositions of memory and its preparation method and application | |
CN101474310A (en) | Chinese medicine for beauty treatment and eliminating spot and preparation method | |
CN102258628B (en) | Chinese medicinal composition with lead removal promoting effect | |
CN101361916A (en) | Chinese herbal preparations for boosting immunity and promoting sleep | |
CN104474251B (en) | Composition and its preparation and the application of function are consolidated with brain tonic | |
CN111418682A (en) | SOD energy-gathering fragrant bag tea capable of improving human body immunity function and preparation method thereof | |
CN102908396B (en) | Chinese medicinal composition for promoting sleeping and preparation method thereof | |
CN103948896A (en) | Composition for resisting altitude stress and application of composition | |
CN108478714A (en) | A kind of paediatrics self-closing disease rehabilitation auxiliary Chinese medicine composition | |
CN102631498B (en) | Chinese medicine composition | |
CN102631496B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
CN103933476B (en) | It is a kind of to treat pharmaceutical composition of intercostal neuralgia and its production and use | |
CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
CN102302569B (en) | Chinese medicinal composition for promoting lead discharging effect | |
CN102631486B (en) | Health care composition | |
CN110251606B (en) | Traditional Chinese medicine composition with sleep improving effect and preparation method thereof | |
CN101850015B (en) | Chinese medicament for treating arteriosclerosis | |
CN108186911A (en) | A kind of mind-tranquilizing brain-strengthening oral liquid and preparation method thereof | |
CN101361811A (en) | Radiation-proof traditional Chinese medicine composition and preparation method thereof | |
CN102935132B (en) | Lead removing traditional Chinese medicine composition | |
CN104000902B (en) | A kind of anti-fatigue medicated wine and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240119 Address after: 528400 No. 10-2 Deneng East Road, Zhongshan Port Community, Torch Development Zone, Zhongshan City, Guangdong Province (Residence Declaration) Patentee after: Guangdong tianbaotang Health Technology Industry Co.,Ltd. Address before: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Effective date of registration: 20240119 Address after: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Address before: 132013 no.3999 Binjiang East Road, Fengman District, Jilin City, Jilin Province Patentee before: BEIHUA University |